Document is current
Any future updates will be listed below
-
Authors
Zarou, Martha M. https://orcid.org/0000-0003-0152-1599
Rattigan, Kevin M. https://orcid.org/0000-0003-0212-0017
Sarnello, Daniele https://orcid.org/0000-0003-4193-2464
Shokry, Engy
Dawson, Amy
Ianniciello, Angela
Dunn, Karen https://orcid.org/0000-0002-6532-970X
Copland, Mhairi https://orcid.org/0000-0002-7655-016X
Sumpton, David https://orcid.org/0000-0002-9004-4079
Vazquez, Alexei https://orcid.org/0000-0003-2764-3244
Helgason, G. Vignir https://orcid.org/0000-0003-1616-132X
-
Funding
Funding for this research was provided by:
Cancer Research UK (C57352/A29754, A25142, A17196, A31287, A17196, A21140)
Kay Kendall Leukaemia Fund (KKL1069)
Bloodwise (18006)
Tenovus
NHS Greater Glasgow and Clyde (GN21ON384)
- License Information
-
More Information
Article History
Received: 12 January 2023
Accepted: 7 February 2024
First Online: 2 March 2024
Competing interests
: M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals. All other authors declare that they have no competing interests.
